Procedures
toxicities, Cancer
DISEASE PROGRESSION, ADVERSE EVENT, ADVERSE EVENT, BLOOD, CANCER
Eligible patients received oral apatinib 500 mg on day 1 to 21, plus oral etoposide 50 mg on day 1 to 14 of a 3-week cycle until disease progression or intolerable toxicities. Etoposide was administered up to six cycles, and patients received apatinib alone after six cycles [Efficacy evaluation was performed using computerized tomography or magnetic resonance imaging every two cycles according to RECIST 1.1 until disease progression or intolerable toxicities. Blood pressure was monitored three times a week. Routine blood, urine, stool, liver and kidney function, electrolytes test and electrocardiogram were performed every cycle. Adverse events (AEs) during the trial were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.